Racial disparity in survival of patients diagnosed with early-onset colorectal cancer

IF 2.7 Q3 ONCOLOGY

Colorectal Cancer Pub Date : 2020-09-01 DOI:10.2217/crc-2020-0015

Kristin Wallace, Hong Li, C. Paulos, D. Lewin, A. Alekseyenko

引用次数: 2

Abstract

Background: Survival is reduced in African–Americans (AAs) diagnosed with colorectal cancer (CRC), especially in those <50 years old, when compared with Caucasian Americans (CAs). Yet, the role of clinicopathologic features of CRCs on racial differences in survival needs further study. Materials & methods: Over 1000 individuals (CA 709, AA 320) diagnosed with CRC were studied for survival via the Cox proportional hazards regression analysis based on race and risk of death in two age groups (<50 or 50+). Results: Risk of death for younger AAs (<50) was elevated compared with younger CAs (hazard ratio [HR] 1.98 [1.26–3.09]). Yet no racial differences in survival was observed in older cohort (50+ years), HR 1.07 (0.88–1.31); p for interaction = 0.01. In younger AAs versus CAs only, colonic location attenuated the risk of death. Conclusion: The tumor location and histology influence the poorer survival observed in younger AAs suggesting these may also influence treatment responses.

查看原文本刊更多论文

早发性结直肠癌患者生存的种族差异

背景:与高加索美国人(CAs)相比，非洲裔美国人(AAs)诊断为结直肠癌(CRC)的生存率降低，尤其是那些<50岁的人。然而，CRCs的临床病理特征在种族生存差异中的作用需要进一步研究。材料与方法:通过基于种族和两个年龄组(<50岁或50岁以上)死亡风险的Cox比例风险回归分析，研究了1000多例确诊为结直肠癌的患者(CA 709, AA 320)的生存率。结果:年龄<50岁的AAs与年龄较小的CAs相比死亡风险升高(风险比[HR] 1.98[1.26-3.09])。然而，在年龄较大的队列(50岁以上)中，生存率没有种族差异，HR为1.07 (0.88-1.31);交互作用P = 0.01。在年轻的AAs和ca中，结肠位置降低了死亡风险。结论:肿瘤的位置和组织学影响年轻AAs患者较差的生存率，这也可能影响治疗反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Colorectal Cancer ONCOLOGY-

自引率

0.00%

发文量

期刊介绍： Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.